S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Organogenesis (ORGO) Stock Price, News & Analysis

$2.84
+0.08 (+2.90%)
(As of 03/28/2024 ET)
Today's Range
$2.72
$2.87
50-Day Range
$2.61
$3.84
52-Week Range
$1.79
$4.70
Volume
253,053 shs
Average Volume
671,489 shs
Market Capitalization
$374.77 million
P/E Ratio
71.02
Dividend Yield
N/A
Price Target
$4.83

Organogenesis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
70.2% Upside
$4.83 Price Target
Short Interest
Bearish
10.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$864,915 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

157th out of 938 stocks

Pharmaceutical Preparations Industry

59th out of 425 stocks

ORGO stock logo

About Organogenesis Stock (NASDAQ:ORGO)

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO Stock Price History

ORGO Stock News Headlines

Organogenesis Holdings Inc. Cl A
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Recap: Organogenesis Hldgs Q4 Earnings
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
A Preview Of Organogenesis Hldgs's Earnings
Organogenesis Holdings Inc - Ordinary Shares - Class A
3 Biotech Stocks Flowing With Investment Potential
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
862
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+70.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$4.95 million
Pretax Margin
2.40%

Debt

Sales & Book Value

Annual Sales
$433.14 million
Cash Flow
$0.23 per share
Book Value
$2.11 per share

Miscellaneous

Free Float
87,096,000
Market Cap
$374.77 million
Optionable
Optionable
Beta
1.59
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

ORGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ORGO shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price target for 2024?

3 brokers have issued 12-month price objectives for Organogenesis' stock. Their ORGO share price targets range from $3.50 to $6.00. On average, they expect the company's share price to reach $4.83 in the next year. This suggests a possible upside of 70.2% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2024?

Organogenesis' stock was trading at $4.09 at the start of the year. Since then, ORGO shares have decreased by 30.6% and is now trading at $2.84.
View the best growth stocks for 2024 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ORGO earnings forecast
.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.03. The company earned $113.75 million during the quarter, compared to the consensus estimate of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 1.81% and a net margin of 1.14%. During the same quarter last year, the company posted $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $445.0 million-$470.0 million, compared to the consensus revenue estimate of $456.0 million.

What other stocks do shareholders of Organogenesis own?
Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.06%), Vanguard Group Inc. (4.06%), Dimensional Fund Advisors LP (1.05%), Charles Schwab Investment Management Inc. (0.63%), Northern Trust Corp (0.47%) and Norges Bank (0.37%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz, Michael W Katz and Starr Wisdom.
View institutional ownership trends
.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners